mar feb jan dec nov oct sep fda drugs february warning letter signature genetics seryx company markets excellent expensive pharmacogenetics program take blood cheek cells analyze dna various genotypes affect body metabolizes certain drugs many psychotropic drugs information may used help prescriber make decisions starting dosages drugs combinations drugs use avoid topic whole 'nother post i could type testing used inappropriately quackwatch page well anyway computer program considered fda device applied fda approval fda telling stop approval obtained wellbutrin bupropion medication guides updated pdf versions medication guides wellbutrin wellbutrin sr updated generic focalin dexmethylphenidate approved new drugs approved merrill goozner comments blog gooznews lowering innovation pharma industry fda starts podcasts fda commissioner dr andy von eschenbach started series drug safety oriented podcasts first one announces series go xml feed subscribe adhd drug warnings fda requiring manufacturers drugs used treat adhd including adderall concerta ritalin strattera develop medication guides warn patients risks cardiovascular sudden death stroke heart attack blood pressure psychiatric mania psychosis aggression side effects vyvanse releases medication guide shire vyvanse lisdexamfetamine dimesylate listed last month name changed vynase new adhd drug prodrug meaning metabolized active drug body advantages said daily less likely abused ie drug abusers prefer stimulants one full approval schedule ii drug full prescribing info see link label info changes nardil phenelzine prescribing info added severe renal impairment renal disease list contraindications added cautions use diabetes added warning drug interaction guanethidine ismelin changes cymbalta duloxetine prescribing info number changes made though i tell substantive lilly receive new indication treatment gad generalized anxiety disorder cymbalta changes effexor xr venlafaxine prescribing info following added precautions section interstitial lung disease eosinophilic pneumonia associated venlafaxine therapy rarely reported possibility adverse events considered venlafaxine treated patients present progressive dyspnea cough chest discomfort patients undergo prompt medical evaluation discontinuation venlafaxine therapy considered zimulti acomplia rimonabant review extended cannibinoid receptor antagonist reviewed weight loss drug guessed blocks munchies even smoking pot final decision approval status april review period extended july i reported november update drug approved mexico latest proposed brand name zimulti hearing drug held june metabolic endocrinologic drugs advisory committee background resource documents ready found warning letter provigil modafinil cephalon got slapped promoting wakefulness promoting drug indicated use narcolepsy obstructive sleep apnea shift work sleep disorder distributing document dr kerasidis states drug effective multiple sclerosis parkinson depression add chronic fatigue syndrome interesting document provided testimony maryland dept health mental hygiene committee responsible making decisions drugs placed medicaid formulary list